Literature DB >> 20495706

Hepatic resection for large hepatocellular carcinoma in the era of UCSF criteria.

Spiros G Delis, Andreas Bakoyiannis, Nikos Tassopoulos, Kostas Athanassiou, Aristotelis Kechagias, Dimitrios Kelekis, Juan Madariaga, Christos Dervenis.   

Abstract

BACKGROUND: Treating patients with hepatocellular carcinoma (HCC) remains a challenge, especially when the disease presents at an advanced stage. The aim of this retrospective study was to determine the efficacy of liver resection in patients who fulfil or exceed University of California San Francisco (UCSF) criteria by assessing longterm outcome.
METHODS: Between 2002 and 2008, 59 patients with large HCC (>5 cm) underwent hepatectomy. Thirty-two of these patients fulfilled UCSF criteria for transplantation (group A) and 27 did not (group B). Disease-free survival and overall survival rates were compared between the two groups after resection and were critically evaluated with regard to patient eligibility for transplant.
RESULTS: In all patients major or extended hepatectomies were performed. There was no perioperative mortality. Morbidity consisted of biliary fistula, abscess, pleural effusion and pneumonia and was significantly higher in patient group B. Disease-free survival rates at 1, 3 and 5 years were 66%, 37% and 34% in group A and 56%, 29% and 26% in group B, respectively (P < 0.01). Survival rates at 1, 3 and 5 years were 73%, 39% and 35% in group A and 64%, 35% and 29% in group B, respectively (P= 0.04). The recurrence rate was higher in group B (P= 0.002).
CONCLUSIONS: Surgical resection, if feasible, is suggested in patients with large HCC and can be performed with acceptable overall and disease-free survival and morbidity rates. In patients eligible for transplantation, resection may also have a place in the management strategy when waiting list time is prolonged for reasons of organ shortage or when the candidate has low priority as a result of a low MELD (model for end-stage liver disease) score.

Entities:  

Year:  2009        PMID: 20495706      PMCID: PMC2785949          DOI: 10.1111/j.1477-2574.2009.00084.x

Source DB:  PubMed          Journal:  HPB (Oxford)        ISSN: 1365-182X            Impact factor:   3.647


  51 in total

1.  Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies.

Authors:  H A EDMONDSON; P E STEINER
Journal:  Cancer       Date:  1954-05       Impact factor: 6.860

2.  Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications.

Authors:  Nazario Portolani; Arianna Coniglio; Sara Ghidoni; Mara Giovanelli; Anna Benetti; Guido Alberto Massimo Tiberio; Stefano Maria Giulini
Journal:  Ann Surg       Date:  2006-02       Impact factor: 12.969

3.  Resection for hepatocellular carcinoma is a good option in Child-Turcotte-Pugh class A patients with cirrhosis who are eligible for liver transplantation.

Authors:  Carlos Margarit; Alfredo Escartín; Lluis Castells; Víctor Vargas; Elena Allende; Itxarone Bilbao
Journal:  Liver Transpl       Date:  2005-10       Impact factor: 5.799

Review 4.  Histological grading and staging of chronic hepatitis.

Authors:  K Ishak; A Baptista; L Bianchi; F Callea; J De Groote; F Gudat; H Denk; V Desmet; G Korb; R N MacSween
Journal:  J Hepatol       Date:  1995-06       Impact factor: 25.083

5.  Impact of UCSF criteria according to pre- and post-OLT tumor features: analysis of 479 patients listed for HCC with a short waiting time.

Authors:  Thomas Decaens; Françoise Roudot-Thoraval; Solange Hadni-Bresson; Carole Meyer; Jean Gugenheim; Francois Durand; Pierre-Henri Bernard; Olivier Boillot; Laurent Sulpice; Yvon Calmus; Jean Hardwigsen; Christian Ducerf; Georges-Philippe Pageaux; Sebastien Dharancy; Olivier Chazouilleres; Daniel Cherqui; Christophe Duvoux
Journal:  Liver Transpl       Date:  2006-12       Impact factor: 5.799

6.  Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival.

Authors:  F Y Yao; L Ferrell; N M Bass; J J Watson; P Bacchetti; A Venook; N L Ascher; J P Roberts
Journal:  Hepatology       Date:  2001-06       Impact factor: 17.425

7.  Liver transplantation outcomes for early-stage hepatocellular carcinoma: results of a multicenter study.

Authors:  Jessica Y Leung; Andrew X Zhu; Fredric D Gordon; Daniel S Pratt; Abigail Mithoefer; Kathryn Garrigan; Adam Terella; Martin Hertl; A Benedict Cosimi; Raymond T Chung
Journal:  Liver Transpl       Date:  2004-11       Impact factor: 5.799

8.  Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis.

Authors:  S Jonas; W O Bechstein; T Steinmüller; M Herrmann; C Radke; T Berg; U Settmacher; P Neuhaus
Journal:  Hepatology       Date:  2001-05       Impact factor: 17.425

Review 9.  Resection and liver transplantation for hepatocellular carcinoma.

Authors:  Josep M Llovet; Myron Schwartz; Vincenzo Mazzaferro
Journal:  Semin Liver Dis       Date:  2005       Impact factor: 6.115

10.  Hepatic resection of hepatocellular carcinoma in patients with cirrhosis: Model of End-Stage Liver Disease (MELD) score predicts perioperative mortality.

Authors:  Swee H Teh; John Christein; John Donohue; Florencia Que; Michael Kendrick; Michael Farnell; Stephen Cha; Patrick Kamath; Raymond Kim; David M Nagorney
Journal:  J Gastrointest Surg       Date:  2005-12       Impact factor: 3.267

View more
  2 in total

1.  Resection and radiofrequency ablation in the treatment of hepatocellular carcinoma: a single-center experience.

Authors:  Koray Karabulut; Federico Aucejo; Hizir Yakup Akyildiz; Allan Siperstein; Eren Berber
Journal:  Surg Endosc       Date:  2011-10-25       Impact factor: 4.584

Review 2.  A Systematic Review and Meta-Analysis Comparing Liver Resection with the Rf-Based Device Habib™-4X with the Clamp-Crush Technique.

Authors:  Kumar Jayant; Mikael H Sodergren; Isabella Reccia; Tomokazu Kusano; Dimitris Zacharoulis; Duncan Spalding; Madhava Pai; Long R Jiao; Kai Wen Huang
Journal:  Cancers (Basel)       Date:  2018-11-08       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.